Results 41 to 50 of about 626,377 (227)

Which is the optimal choice in lipid-lowering therapy for reducing major cardiovascular events? a network meta-analysis

Frontiers in Pharmacology
BackgroundCurrently, there are various lipid-lowering therapies in clinical practice, and the emergence of PCSK9 inhibitors has undoubtedly added a valuable tool to lipid-lowering strategies.
Qiang Niu, Qilei Wang, Feng Chen, Bo Li
doaj   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +2 more sources

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

, 2022
Xiaoming Jia,1 Mahmoud Al Rifai,1 Anum Saeed,2 Christie M Ballantyne,1 Salim S Virani1,3 1Department of Medicine, Baylor College of Medicine, Houston, TX, USA; 2Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA ...
Virani SS, Ballantyne CM, Jia X, Al Rifai M, Saeed A   +4 more
core  

Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study

Brain and Behavior
Background In addition to lowering cholesterol levels, the proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has a variety of effects, including anti‐neuroapoptosis.
Qiang Huang, Qin Zhang, Bei Cao
doaj   +1 more source

The E3 ubiquitin ligase c-IAP1 regulates PCSK9-mediated LDLR degradation: Linking the TNF-α pathway to cholesterol uptake [PDF]

, 2010
Proprotein convertase subtilisin/kexin type 9 (PCSK9), in addition to LDLR (low-density lipoprotein receptor) and APOB (apolipoprotein B), is one of three loci implicated in autosomal dominant hypercholesterolaemia (ADH)^1^.
Lizhi Liu, Weiming Xu
core  

USP5 Stabilizes TGFBR1 to Drive Vascular Smooth Muscle Cell Senescence and Atherosclerosis

Advanced Science, EarlyView.
This study reveals that USP5 drives vascular smooth muscle cell senescence and atherosclerosis by stabilizing TGFBR1, suppressing IDH2, and promoting glycolytic reprogramming, identifying the USP5‐TGFBR1‐IDH2 axis as a potential therapeutic target. ABSTRACT Vascular smooth muscle cell (VSMC) senescence contributes importantly to atherosclerotic plaque ...
Xinhai Cui, Yuanlong Hu, Lin Lin, Lei Zhang, Chao Li, Yunlun Li   +5 more
wiley   +1 more source

PCSK9 deficiency alters brain lipid composition without affecting brain development and function

Frontiers in Molecular Neuroscience, 2023
PCSK9 induces lysosomal degradation of the low-density lipoprotein (LDL) receptor (LDLR) in the liver, hereby preventing removal of LDL cholesterol from the circulation.
Angela Pärn, Ditte Olsen, Jürgen Tuvikene, Jürgen Tuvikene, Mathias Kaas, Ekaterina Borisova, Ekaterina Borisova, Mesut Bilgin, Mie Elhauge, Joachim Vilstrup, Joachim Vilstrup, Peder Madsen, Peder Madsen, Mateusz C. Ambrozkiewicz, Roman U. Goz, Tõnis Timmusk, Tõnis Timmusk, Victor Tarabykin, Victor Tarabykin, Camilla Gustafsen, Camilla Gustafsen, Simon Glerup, Simon Glerup   +22 more
doaj   +1 more source

Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis

Advanced Science, EarlyView.
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Yi Duan, Yijie Qiu, Yan Zhu, Quan Wang, Jiangtao Lin, Yourong Duan, Qi Wang, Yi Dong   +7 more
wiley   +1 more source

PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort

Biomedicine & Pharmacotherapy, 2022
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have emerged as a therapeutic option for patients with hypercholesterolemia who do not attain low-density lipoprotein cholesterol (LDL-C) goals and/or are intolerant to other lipid-lowering drugs.
Juan, Vicente-Valor, Xandra, García-González, Sara, Ibáñez-García, María Esther, Durán-García, Ana, de Lorenzo-Pinto, Carmen, Rodríguez-González, Irene, Méndez-Fernández, Juan Carlos, Percovich-Hualpa, Ana, Herranz-Alonso, María, Sanjurjo-Sáez   +9 more
openaire   +2 more sources

PCSK9: NEW VICTORY AND HORIZONS

Атеросклероз, 2018
The review presents the latest data from the world scientific literature of clinical studies of inhibitors protoprotein convertasesubtilisin/kexin 9 type (PCSK9).
M. O. Smolina, K. S. Benimetskaya, Yu. I. Ragino, M. I. Voevoda   +3 more
doaj   +1 more source